Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Good news flowed in at Bristol-Myers Squibb (BMY - Analyst Report) and partner AstraZeneca (AZN - Analyst Report) from the UK recently when the National Institute for Health and Clinical Excellence (NICE) issued a Final Appraisal Determination (FAD) for their type II diabetes drug Forxiga (dapagliflozin).

NICE has recommended the use of the product for adults suffering from type II diabetes in combination with metformin and in combination with insulin with or without other oral anti-diabetic drugs in England and Wales.

We note that the FAD will act as the basis for the final NICE guidance. We believe a favorable decision from NICE will increase the access of Forxiga by patients. Forxiga sales in the first quarter of 2013, as recorded by Bristol-Myers, were $3 million.

We remind investors that the European Commission approved Forxiga (once daily) in the EU, in Nov 2012, for improving glycemic control in adults suffering from type II diabetes along with lifestyle management and other glucose-lowering products, such as insulin. Forxiga can be used as a monotherapy in patients who are intolerant to metformin.

The EU approval did not come as a surprise as earlier in Apr 2012 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion regarding the approval of Forxiga in the EU.

The US approval path has been bumpy for the drug. In Jan 2012, Bristol-Myers and AstraZeneca received a complete response letter (CRL) from the FDA for Forxiga. The companies were seeking approval of the drug as an adjunct to diet and exercise for improving glycemic control in adults suffering from type II diabetes.
 
The US regulatory body while issuing the CRL asked for additional data for better assessment of the candidate’s risk-benefit profile. Bristol-Myers intends to resubmit the new drug application to the FDA in mid-2013.

Both AstraZeneca and Bristol-Myers carry a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. and Salix Pharmaceuticals (SLXP - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%